{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:18:33Z","timestamp":1795177113283,"version":"4.10.3"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["PI22\/01804"],"award-info":[{"award-number":["PI22\/01804"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neurogastroenterology and Motility"},{"DOI":"10.13039\/100031734","name":"Spanish Association of Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CM23\/00076"],"award-info":[{"award-number":["CM23\/00076"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1 R01 AR081382-01A1"],"award-info":[{"award-number":["1 R01 AR081382-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Gastrointestinal involvement (GI) in SSc is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Studies investigating the effects of prokinetic agents on GI function and\/or GI symptoms in patients with SSc were systematically identified on PubMed and Embase. A qualitative data synthesis was conducted, given the (anticipated) wide heterogeneity in study designs, interventions and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-one studies evaluating the effects of prokinetics in patients with SSc were included. Thirteen studies focused on GI motility using objective tests, eight assessed clinical responses, and six evaluated both. Cisapride (n\u2009=\u20095 studies), metoclopramide (n\u2009=\u20097 studies), octreotide (n\u2009=\u20094 studies) and prucalopride (n\u2009=\u20091 study) were among the most studied prokinetics, with varying effects on different GI anatomical regions. While metoclopramide consistently improved overall GI motility, other prokinetics provided selective benefits; cisapride improved gastric emptying and colonic motility, but not oesophageal motility, and octreotide improved small bowel motility but delayed gastric emptying. Regarding symptomatic improvement, only prucalopride was evaluated using a validated patient questionnaire, showing improvement in both upper and lower GI symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Prokinetic drugs may improve GI motility and symptoms in patients with SSc. There is an unmet need for future well-designed studies to refine patient stratification and optimize treatment outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf064","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:42:23Z","timestamp":1738384943000},"page":"3266-3279","source":"Crossref","is-referenced-by-count":16,"title":["The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-6317","authenticated-orcid":false,"given":"Alberto","family":"Ezquerra-Dur\u00e1n","sequence":"first","affiliation":[{"name":"Neurogastroenterology and Motility Unit, Gastroenterology Department, Hospital Clinic of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-1539","authenticated-orcid":false,"given":"Luis G","family":"Alcala-Gonzalez","sequence":"additional","affiliation":[{"name":"Digestive System Research Unit, Department of Digestive Diseases, Vall d\u2019Hebron University Hospital , Barcelona,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (Ciberehd), Instituto de Salud Carlos III , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-507X","authenticated-orcid":false,"given":"Alfredo","family":"Guillen-del-Castillo","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-9029","authenticated-orcid":false,"given":"Carmen P","family":"Sime\u00f3n-Aznar","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-6592","authenticated-orcid":false,"given":"Elizabeth","family":"Barba","sequence":"additional","affiliation":[{"name":"Neurogastroenterology and Motility Unit, Gastroenterology Department, Hospital Clinic of Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7097-1492","authenticated-orcid":false,"given":"Carolina","family":"Malagelada","sequence":"additional","affiliation":[{"name":"Digestive System Research Unit, Department of Digestive Diseases, Vall d\u2019Hebron University Hospital , Barcelona,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (Ciberehd), Instituto de Salud Carlos III , Madrid,","place":["Spain"]},{"name":"Department of Medicine, Universitat Autonoma de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-4909","authenticated-orcid":false,"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre , Manchester,","place":["United Kingdom"]},{"name":"Northern Care Alliance NHS Foundation Trust, Salford Care Organisation , Salford,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6461-8940","authenticated-orcid":false,"given":"Zsuzsanna H","family":"McMahan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, UTHealth Houston , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025052703534169500_keaf064-B1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025052703534169500_keaf064-B2","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11&lt;2437::AID-ANR10&gt;3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2025052703534169500_keaf064-B3","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/gut.2005.086074","article-title":"A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma)","volume":"55","author":"Roberts","year":"2006","journal-title":"Gut"},{"key":"2025052703534169500_keaf064-B4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","article-title":"Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls","volume":"46","author":"D'Angelo","year":"1969","journal-title":"Am J Med"},{"key":"2025052703534169500_keaf064-B5","first-page":"115","article-title":"The gastric wall in systemic sclerosis patients: a morphological study","volume":"115","author":"Manetti","year":"2010","journal-title":"Ital J Anat Embryol Arch Ital Anat Ed Embriologia"},{"key":"2025052703534169500_keaf064-B6","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/rheumatology\/ker153","article-title":"Internal anal sphincter atrophy in patients with systemic sclerosis","volume":"50","author":"Thoua","year":"2011","journal-title":"Rheumatol Oxf Engl"},{"key":"2025052703534169500_keaf064-B7","doi-asserted-by":"publisher","first-page":"101666","DOI":"10.1016\/j.berh.2021.101666","article-title":"A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis","volume":"35","author":"Kaniecki","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025052703534169500_keaf064-B8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/acr.24488","article-title":"Relationship between gastrointestinal transit, Medsger gastrointestinal severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in patients with systemic sclerosis","volume":"74","author":"McMahan","year":"2022","journal-title":"Arthritis Care Res"},{"key":"2025052703534169500_keaf064-B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.17235\/reed.2023.10038\/2023","article-title":"Current insights on chronic intestinal dysmotility: pseudo-obstruction and enteric dysmotility","volume":"116","author":"Alcal\u00e1 Gonz\u00e1lez","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"2025052703534169500_keaf064-B10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025052703534169500_keaf064-B11","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"Denton","year":"2024","journal-title":"Rheumatol Oxf Engl"},{"key":"2025052703534169500_keaf064-B12","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"2025052703534169500_keaf064-B13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025052703534169500_keaf064-B14","author":"Wells","year":"2013"},{"key":"2025052703534169500_keaf064-B15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.7326\/0003-4819-94-6-749","article-title":"Abnormal colonic motility in progressive systemic sclerosis","volume":"94","author":"Battle","year":"1981","journal-title":"Ann Intern Med"},{"key":"2025052703534169500_keaf064-B16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0016-5085(82)80192-3","article-title":"Interdigestive motor activity in patients with systemic sclerosis","volume":"83","author":"Rees","year":"1982","journal-title":"Gastroenterology"},{"key":"2025052703534169500_keaf064-B17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","article-title":"Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma","volume":"325","author":"Soudah","year":"1991","journal-title":"N Engl J Med"},{"key":"2025052703534169500_keaf064-B18","first-page":"550","article-title":"Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term","volume":"89","author":"Fiorucci","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"2025052703534169500_keaf064-B19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3109\/00365529409092515","article-title":"Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients","volume":"29","author":"Fiorucci","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"2025052703534169500_keaf064-B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/art.1780200105","article-title":"Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS","volume":"20","author":"Ramirez-Mata","year":"1977","journal-title":"Arthritis Rheum"},{"key":"2025052703534169500_keaf064-B21","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.1987.00370090075014","article-title":"Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities","volume":"147","author":"Johnson","year":"1987","journal-title":"Arch Intern Med"},{"key":"2025052703534169500_keaf064-B22","first-page":"810","article-title":"Scintigraphic detection of metoclopramide esophageal stimulation in progressive systemic sclerosis","volume":"28","author":"Drane","year":"1987","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"2025052703534169500_keaf064-B23","first-page":"685","article-title":"M. Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities","volume":"23","author":"Mercado","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025052703534169500_keaf064-B24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2125.1991.tb05593.x","article-title":"The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study","volume":"31","author":"Kahan","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"2025052703534169500_keaf064-B25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000200715","article-title":"Effects of cisapride on the esophageal motor function of patients with progressive systemic sclerosis or mixed connective tissue disease","volume":"49","author":"Limburg","year":"1991","journal-title":"Digestion"},{"key":"2025052703534169500_keaf064-B26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0016-5085(87)91020-1","article-title":"Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis","volume":"93","author":"Horowitz","year":"1987","journal-title":"Gastroenterology"},{"key":"2025052703534169500_keaf064-B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s100670200010","article-title":"Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis","volume":"21","author":"Wang","year":"2002","journal-title":"Clin Rheumatol"},{"key":"2025052703534169500_keaf064-B28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s100670200072","article-title":"Effects of cisapride on colonic transit in patients with progressive systemic sclerosis","volume":"21","author":"Wang","year":"2002","journal-title":"Clin Rheumatol"},{"key":"2025052703534169500_keaf064-B29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/00042737-200511000-00009","article-title":"Small intestinal manometry in patients with systemic sclerosis","volume":"17","author":"Sj\u00f6lund","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025052703534169500_keaf064-B30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/rheumatology\/kel203","article-title":"Outcome of small-bowel motor impairment in systemic sclerosis\u2014a prospective manometric 5-yr follow-up","volume":"46","author":"Marie","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"key":"2025052703534169500_keaf064-B31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13075-017-1340-y","article-title":"Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study","volume":"19","author":"Vigone","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025052703534169500_keaf064-B32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0022-2143(98)90133-0","article-title":"Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications","volume":"132","author":"Sridhar","year":"1998","journal-title":"J Lab Clin Med"},{"key":"2025052703534169500_keaf064-B33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1507\/endocrj.EJ14-0088","article-title":"Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis","volume":"61","author":"Ariyasu","year":"2014","journal-title":"Endocr J"},{"key":"2025052703534169500_keaf064-B34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/rheumatology\/kew216","article-title":"Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial","volume":"56","author":"Foocharoen","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"key":"2025052703534169500_keaf064-B35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/RHU.0b013e3180645d2a","article-title":"Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients","volume":"13","author":"Nikou","year":"2007","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"2025052703534169500_keaf064-B36","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3899\/jrheum.110225","article-title":"Minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument","volume":"38","author":"Khanna","year":"2011","journal-title":"J Rheumatol"},{"key":"2025052703534169500_keaf064-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33549\/physiolres.930255","article-title":"Neurohumoral control of gastrointestinal motility","volume":"52","author":"Hansen","year":"2003","journal-title":"Physiol Res"},{"key":"2025052703534169500_keaf064-B38","doi-asserted-by":"publisher","first-page":"700884","DOI":"10.3389\/fendo.2021.700884","article-title":"Motilin comparative study: structure, distribution, receptors, and gastrointestinal motility","volume":"12","author":"Kitazawa","year":"2021","journal-title":"Front Endocrinol"},{"key":"2025052703534169500_keaf064-B39","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/art.1780370902","article-title":"Gastrointestinal motility disorders in scleroderma","volume":"37","author":"Sjogren","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2025052703534169500_keaf064-B40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41584-022-00900-6","article-title":"Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management","volume":"19","author":"McMahan","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025052703534169500_keaf064-B41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/key350","article-title":"Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality","volume":"58","author":"Richard","year":"2019","journal-title":"Rheumatol Oxf Engl"},{"key":"2025052703534169500_keaf064-B42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semarthrit.2019.05.005","article-title":"Evaluation of risk factors for pseudo-obstruction in systemic sclerosis","volume":"49","author":"Dein","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025052703534169500_keaf064-B43","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1572-0241.2002.05396.x","article-title":"Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride","volume":"97","author":"Boeckxstaens","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2025052703534169500_keaf064-B44","doi-asserted-by":"publisher","first-page":"keae481","DOI":"10.1093\/rheumatology\/keae481","article-title":"Gastrointestinal dysmotility is associated with proton pump inhibitor refractory esophagitis in patients with systemic sclerosis","author":"Alcala-Gonzalez","year":"2024","journal-title":"Rheumatol Oxf Engl"},{"key":"2025052703534169500_keaf064-B45","doi-asserted-by":"publisher","first-page":"e14774","DOI":"10.1111\/nmo.14774","article-title":"Prokinetics-safety and efficacy: The European Society of Neurogastroenterology and Motility\/The American Neurogastroenterology and Motility Society expert review","volume":"36","author":"Bor","year":"2024","journal-title":"Neurogastroenterol Motil"},{"key":"2025052703534169500_keaf064-B46","doi-asserted-by":"publisher","first-page":"e004532","DOI":"10.1136\/rmdopen-2024-004532","article-title":"Arrhythmia in patients with systemic sclerosis: incidence, risk factors and impact on mortality in a Swedish register-based study","volume":"10","author":"Bairkdar","year":"2024","journal-title":"RMD Open"},{"key":"2025052703534169500_keaf064-B47","doi-asserted-by":"publisher","first-page":"e007953","DOI":"10.1136\/bmjopen-2015-007953","article-title":"Minimally important difference estimates and methods: a protocol","volume":"5","author":"Johnston","year":"2015","journal-title":"BMJ Open"},{"key":"2025052703534169500_keaf064-B48","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025052703534169500_keaf064-B49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1365-2125.2008.03249.x","article-title":"Cisapride and ventricular arrhythmia","volume":"66","author":"Hennessy","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2025052703534169500_keaf064-B50","doi-asserted-by":"publisher","first-page":"e13617","DOI":"10.1111\/nmo.13617","article-title":"Gastroparesis, metoclopramide, and tardive dyskinesia: risk revisited","volume":"31","author":"Al-Saffar","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"2025052703534169500_keaf064-B51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.semarthrit.2017.12.007","article-title":"Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis","volume":"48","author":"Ahuja","year":"2018","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf064\/61771883\/keaf064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3266\/61771883\/keaf064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3266\/61771883\/keaf064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:53:57Z","timestamp":1748332437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3266\/8002920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf064","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,5]]}}}